Byondis B.V.: Byondis and medac Enter Into License and Colla

SYD985 Marketing Authorization Application Soon to Be Submitted to the EMA NIJMEGEN, Netherlands and WEDEL, Germany, May 3, 2022 /PRNewswire/ -- Byondis B.V., an independent, Dutch clinical

Related Keywords

Germany , Netherlands , United Kingdom , Nijmegen , Gelderland , Dutch , Prnewswire Byondis , Marco Timmers , Kostenloser Wertpapierhandel , Jacques Lemmens , European Medicines Agency , Regulatory Agency , Authorization Application Soon , Collaboration Agreement , Supply Agreement , United Kingdom Medicines , Byondis Founder , Chairman Jacques Lemmens , Managing Director , Marketing Authorization Application , Next Generation Antibody Drug , Good Manufacturing Practice , Byondis , Medac , Winter , Into , License , Collaboration , Supply , Agreements , Anti , Ther2 , Rastuzumab , Uocarmazine , Yd985 ,